| Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML) (NCT07223814) | Stichting Hemato-Oncologie voor Volwassenen Nederland | 2026-03-01 |
| Ivosidenib and Azacitidine With or Without Venetoclax in Adult Patients With Newly Diagnosed IDH1-Mutated AML or MDS/AML Considered Ineligible for Intensive Chemotherapy (NCT07075016) | Stichting Hemato-Oncologie voor Volwassenen Nederland | 2025-08-05 |
| Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML (NCT06652438) | Stichting Hemato-Oncologie voor Volwassenen Nederland | 2025-05-05 |
| Tasquinimod in Patients with Myelofibrosis Refractory to or Intolerant for JAK2 Inhibition (NCT06605586) | Stichting Hemato-Oncologie voor Volwassenen Nederland | 2025-02-20 |
| Prevention of Anthracycline-Induced Cardiac Dysfunction With Dexrazoxane in Patients With Diffuse Large-B Cell Lymphoma (NCT06220032) | Stichting Hemato-Oncologie voor Volwassenen Nederland | 2024-08-15 |
| Zanubrutinib in Primary Cold Agglutinin Disease (NCT06067048) | Stichting Hemato-Oncologie voor Volwassenen Nederland | 2024-07-26 |
| FeAsiBility of a Treatment Free Interval in Newly Diagnosed MM Patients Treated With Daratumumab-lenalidomide-dexamethasone (HOVON174MM) (NCT06187441) | Stichting Hemato-Oncologie voor Volwassenen Nederland | 2024-05-14 |
| Venetoclax Treatment (26 Cycles) With 6 Cycles or 12 Cycles of Epcoritamab in Patients With Relapsed or Refractory CLL or SLL (NCT05791409) | Stichting Hemato-Oncologie voor Volwassenen Nederland | 2024-04-10 |
| A Trial to Assess Cobicistat Boosted Venetoclax in Combination With Azacitidine in Adult Patients With Newly Diagnosed AML (NCT06014489) | Stichting Hemato-Oncologie voor Volwassenen Nederland | 2024-01-17 |
| Tislelizumab, Gemcitabine and Cisplatin for R/R Hodgkin Lymphoma Followed by Tislelizumab Consolidation in Patients in Metabolic Complete Remission (NCT05502250) | Stichting Hemato-Oncologie voor Volwassenen Nederland | 2023-07-14 |
| Study to Assess an Interphase Cycle With Flotetuzumab. (NCT05063123) | Stichting Hemato-Oncologie voor Volwassenen Nederland | 2022-01-01 |
| CLL Induction Treatment With Venetoclax and Ibrutinib, Followed by Ibrutinib and Obinutuzumab in Patients With MRD. (NCT04639362) | Stichting Hemato-Oncologie voor Volwassenen Nederland | 2020-12-29 |
| REtreatment With VEnetoclax and Acalabrutinib After Venetoclax Limited Duration (REVEAL) (NCT04523428) | Stichting Hemato-Oncologie voor Volwassenen Nederland | 2020-12-23 |
| A National Study for Blood Based Response Monitoring of B-cell Lymphoma Patients (NCT04139252) | Stichting Hemato-Oncologie voor Volwassenen Nederland | 2020-03-17 |
| A Study of Gilteritinib Versus Midostaurin in Combination With Induction and Consolidation Therapy Followed by One-year Maintenance in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndromes With Excess Blasts-2 With FLT3 Mutations Eligible for Intensive Chemotherapy (NCT04027309) | Stichting Hemato-Oncologie voor Volwassenen Nederland | 2019-12-20 |
| Tolerability and Efficacy of Midostaurin to 10-day Decitabine in Unfit Adult AML and High Risk MDS Patients (NCT04097470) | Stichting Hemato-Oncologie voor Volwassenen Nederland | 2019-12-05 |
| A Study of Ivosidenib or Enasidenib in Combination With Induction Therapy and Consolidation Therapy, Followed by Maintenance Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myedysplastic Syndrome EB2, With an IDH1 or IDH2 Mutation, Respectively, Eligible for Intensive Chemotherapy (NCT03839771) | Stichting Hemato-Oncologie voor Volwassenen Nederland | 2019-03-01 |
| Carfilzomib, Lenalidomide and Dexamethasone Versus Lenalidomide and Dexamethasone in High- Risk SMM (NCT03673826) | Stichting Hemato-Oncologie voor Volwassenen Nederland | 2018-11-19 |
| The Feasibility and Clinical Efficacy of Atezolizumab Consolidation Treatment in High Risk (IPI > 2) DLBCL (NCT03463057) | Stichting Hemato-Oncologie voor Volwassenen Nederland | 2018-08-30 |
| DA-EPOCH-R Induction Followed by Nivolumab Consolidation in Newly Diagnosed MYC, BCL2 and/or BCL6 Rearranged HGBL (NCT03620578) | Stichting Hemato-Oncologie voor Volwassenen Nederland | 2018-08-01 |
| Blinatumomab Added to Prephase and Consolidation Therapy in Precursor B-acute Lymphoblastic Leukemia in Adults. (NCT03541083) | Stichting Hemato-Oncologie voor Volwassenen Nederland | 2018-06-04 |
| Myelofibrosis Treated With Pacritinib Before aSCT. (HOVON134MF) (NCT03645824) | Stichting Hemato-Oncologie voor Volwassenen Nederland | 2018-06-04 |
| Phase I-II Study in CD30 Positive Diffuse Large B-cell Lymphoma Patients Refractory to First Line Chemotherapy or in First Relapse (NCT03356054) | Stichting Hemato-Oncologie voor Volwassenen Nederland | 2018-03-05 |
| A Prospective, Multicenter, Phase-II Trial of Ibrutinib Plus Venetoclax in Patients With Creatinine Clearance >= 30 ml/Min Who Have Relapsed or Refractory Chronic Lymphocytic Leukemia (RR-CLL) With or Without TP53 Aberrations (NCT03226301) | Stichting Hemato-Oncologie voor Volwassenen Nederland | 2017-06-23 |
| Study to Compare VMP With HDM Followed by VRD Consolidation and Lenalidomide Maintenance in Patients With Newly Diagnosed Multiple Myeloma (NCT01208766) | Stichting Hemato-Oncologie voor Volwassenen Nederland | 2011-01-01 |
| Cytarabine and Daunorubicin With or Without Gemtuzumab Ozogamicin in Treating Older Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes (NCT00121303) | Stichting Hemato-Oncologie voor Volwassenen Nederland | 2005-01-01 |